Chris Schott
Stock Analyst at JP Morgan
(1.1)
# 1825
Out of 5,329 analysts
128
Total ratings
49.33%
Success rate
2.93%
Average return
Main Sectors:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
REGN Regeneron Pharmaceut... | Maintains: Overweight | 1100 1000 | 607.35 | 64.65% | 6 | Mar 31, 2025 | |
GILD Gilead Sciences | Maintains: Overweight | 120 130 | 104.47 | 24.44% | 5 | Mar 27, 2025 | |
AMRX Amneal Pharmaceutica... | Upgrades: Overweight | 9 12 | 7.88 | 52.28% | 2 | Feb 24, 2025 | |
ABBV AbbVie | Maintains: Overweight | 210 200 | 196.56 | 1.75% | 2 | Nov 13, 2024 | |
BIIB Biogen | Maintains: Neutral | 220 210 | 122.09 | 72% | 3 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 16 18 | 16.02 | 12.36% | 9 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 630 575 | 481.55 | 19.41% | 7 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 225 230 | 159.28 | 44.4% | 2 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 1050 1100 | 828.86 | 32.71% | 19 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | 18 20 | 9.41 | 112.54% | 2 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 48 41 | 25.7 | 59.53% | 8 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 45 42 | 32.82 | 27.97% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Neutral | 270 | 282.65 | -4.48% | 1 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 36 34 | 24.18 | 40.61% | 7 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 120 125 | 84.08 | 48.67% | 6 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 13 14 | 8.62 | 62.41% | 2 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 13 11 | 1.08 | 918.52% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 2 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 24 20 | 9.79 | 104.29% | 3 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 175 150 | n/a | n/a | 3 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 4 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 74 78 | 49.94 | 56.19% | 4 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 110 | n/a | n/a | 1 | Sep 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 700 950 | 3.89 | 24321.59% | 4 | May 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 5 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 2 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 2 | May 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | 9 | n/a | n/a | 6 | May 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 45 50 | 27.02 | 85.05% | 3 | Nov 2, 2018 |